Covalon to showcase advanced medical coating capabilities at AUA annual meeting

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced it will be showcasing  its advanced medical coating capabilities, including its SilverCoat^TM Antimicrobial Silicone Foley Catheter as well as its recently FDA cleared IV Clear™ antimicrobial silicone adhesive film dressing  from May 19^th to May 23^rd at the American Urological Association 2012 Annual Meeting ("AUA") in Atlanta, Georgia.

"We are looking forward to presenting our SilverCoat™ Antimicrobial Silicone Foley Catheter, with its lubricious and antimicrobial coating at the AUA," said Brian Pedlar, Covalon's Chief Executive Officer. "We have demonstrated that our antimicrobial coating outperforms market-leading silver coated Foley catheters in killing the bacteria most commonly associated with urinary tract infections. The AUA provides Covalon with a great opportunity to showcase our urological care products to an international audience, including close to three hundred leading manufacturers, wholesalers and distributors."

Urinary tract infections have been identified by the United States Center for Disease Control as the most common type of healthcare associated infection, of which 75% are associated with a urinary catheter, often referred to as CAUTIs.  The Centers for MediCare and Medicaid Services are no longer reimbursing medical institutions for the treatment of CAUTIs.

Now in its 107th year, the AUA Annual Meeting is the largest gathering of urologists in the world, providing unparalleled access to groundbreaking research, new guidelines and the latest advances in urologic medicine.

Covalon will also be showcasing its advanced wound and antimicrobial silicone adhesive technology. These exciting new products will be available for license or distribution, following regulatory clearance to our growing domestic and international distribution channels and to medical product companies who are looking to license breakthrough new products.